HIGHOutside partyProduct / Revenue mix
84%
lymphedema products
“10-K Item 1A: 'Our lymphedema products accounted for 84% and 89% of our revenue for the years ended December 31, 2025 and 2024, respectively.'”
TCMD · Concentration risk · 10-K extracted
Tactile Systems Technology (TCMD) concentration risks
Updated
The most significant concentration Tactile Systems Technology discloses is lymphedema products at 84%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Tactile Systems Technology’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
single-source component suppliers
“10-K Item 1A: 'We utilize third-party, single-source suppliers for some components and materials used in our products, and the loss of any of these suppliers could have an adverse impact on our business.'”
HIGHOutside partyCounterparty
DME providers (AffloVest distribution)
“10-K Item 1A: 'because we fully rely on DME providers related to sales of our AffloVest product, any disruption affecting those DMEs could adversely impact our results'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Tactile Systems Technology's concentration risks are all high-share and reinforce one another around a single therapeutic category. Lymphedema products accounted for 84% of revenue, a high-share dependency exposure on one product line. That same product line depends on third-party, single-source suppliers for some components and materials, a high-share dependency exposure on the supply side, and the company fully relies on durable medical equipment (DME) providers for distribution of its AffloVest product, another high-share dependency exposure on the distribution side. These three exposures stack on top of each other rather than diversifying the risk: the revenue base is concentrated in lymphedema products, the inputs to at least part of that product line run through single-source suppliers, and a related product's route to market runs entirely through DME providers. A disruption at any single link — a supplier, a DME relationship, or demand for lymphedema products specifically — would have an outsized effect given how little of the business sits outside this cluster. All three are dependency-type risks tied to specific counterparties or product categories rather than diffuse structural features, meaning idiosyncratic shocks to any one relationship could disproportionately affect results relative to a more diversified device maker.
For the engine’s reasoning on TCMD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| TCMD● | Tactile Systems Technology, Inc | 3 | 0 | 0 | 3 |
| AVNS | Avanos Medical, Inc. | 2 | 0 | 1 | 3 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AHCO | AdaptHealth Corp. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.